Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with unusual precision and stability. PCCs offer the promise of superior stability, lower cost and faster creation compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses.
Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging™ medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside™ brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.
Now an independent company, Indi Molecular launched as a spinout from its parent company Indi (Integrated Diagnostics) in 2013 with a $1.8 million seed round led by InterWest Partners together with several angel investors. For more information visit www.IndiMolecular.com.